9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NMTR vs. ALBT, DRMA, EVAX, ORGS, REVB, NBY, VRAX, BIVI, GRI, and CEROShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include Avalon GloboCare (ALBT), Dermata Therapeutics (DRMA), Evaxion A/S (EVAX), Orgenesis (ORGS), Revelation Biosciences (REVB), NovaBay Pharmaceuticals (NBY), Virax Biolabs Group (VRAX), BioVie (BIVI), GRI Bio (GRI), and CERo Therapeutics (CERO). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Its Competitors Avalon GloboCare Dermata Therapeutics Evaxion A/S Orgenesis Revelation Biosciences NovaBay Pharmaceuticals Virax Biolabs Group BioVie GRI Bio CERo Therapeutics 9 Meters Biopharma (NASDAQ:NMTR) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk. Which has more volatility & risk, NMTR or ALBT? 9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Is NMTR or ALBT more profitable? 9 Meters Biopharma has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,451.94%. Avalon GloboCare's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets 9 Meters BiopharmaN/A -584.97% -159.45% Avalon GloboCare -1,451.94%N/A -65.14% Which has stronger valuation and earnings, NMTR or ALBT? Avalon GloboCare has higher revenue and earnings than 9 Meters Biopharma. Avalon GloboCare is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/AAvalon GloboCare$1.33M3.24-$7.90M-$19.96-0.11 Do institutionals & insiders believe in NMTR or ALBT? 22.3% of 9 Meters Biopharma shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by company insiders. Comparatively, 37.3% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor NMTR or ALBT? In the previous week, Avalon GloboCare had 4 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 4 mentions for Avalon GloboCare and 0 mentions for 9 Meters Biopharma. Avalon GloboCare's average media sentiment score of 0.49 beat 9 Meters Biopharma's score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the news media. Company Overall Sentiment 9 Meters Biopharma Neutral Avalon GloboCare Neutral SummaryAvalon GloboCare beats 9 Meters Biopharma on 7 of the 12 factors compared between the two stocks. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$138.55M$5.66B$9.82BDividend YieldN/A3.74%3.79%4.07%P/E Ratio0.003.8230.5825.12Price / SalesN/A4,361.86462.14114.81Price / CashN/A13.1937.4059.05Price / BookN/A44.949.096.18Net Income-$43.77M-$90.99M$3.25B$264.89M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A0.0020Gap UpALBTAvalon GloboCare1.2017 of 5 stars$2.15-3.6%N/A-66.2%$4.06M$1.33M-0.115Positive NewsEarnings ReportUpcoming EarningsShort Interest ↑DRMADermata Therapeutics3.2754 of 5 stars$6.09-1.2%$30.00+392.9%-71.0%$3.90MN/A-0.378Earnings ReportShort Interest ↓EVAXEvaxion A/S1.8769 of 5 stars$2.78+0.4%$10.00+259.7%-80.7%$3.89M$3.34M-2.4060News CoverageEarnings ReportORGSOrgenesis1.4346 of 5 stars$0.79-1.3%N/AN/A$3.79M$662K0.00150Short Interest ↑REVBRevelation Biosciences0.1638 of 5 stars$2.44+2.3%N/A-94.0%$3.73MN/A-0.0410Short Interest ↑NBYNovaBay Pharmaceuticals1.6716 of 5 stars$0.61+1.5%$0.85+39.3%+25.5%$3.55M$9.78M-0.0130News CoverageVRAXVirax Biolabs Group3.4406 of 5 stars$0.77+1.6%$3.00+288.6%-44.6%$3.35M$10K0.005Positive NewsShort Interest ↓BIVIBioVie0.7769 of 5 stars$1.70-5.3%N/A-93.0%$3.15MN/A-0.0210Upcoming EarningsGap UpHigh Trading VolumeGRIGRI Bio2.3538 of 5 stars$1.25+7.3%$22.00+1,660.0%-83.0%$3.13MN/A-0.111News CoverageEarnings ReportShort Interest ↑Gap DownCEROCERo Therapeutics3.3094 of 5 stars$7.94-0.8%$45.00+467.1%-97.3%$3.11MN/A0.008Short Interest ↑ Related Companies and Tools Related Companies ALBT Alternatives DRMA Alternatives EVAX Alternatives ORGS Alternatives REVB Alternatives NBY Alternatives VRAX Alternatives BIVI Alternatives GRI Alternatives CERO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMTR) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access